PGNY Progyny Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PGNY

Price (delayed)

$31.19

Market cap

$2.44B

P/E Ratio

38.99

Dividend/share

N/A

EPS

$0.8

Enterprise value

$2.33B

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 52
Relative Profitability: Rel. Profitability: 64

Progyny is a leading fertility benefits management company in the US. The company is redefining fertility and family building benefits, proving that a comprehensive and inclusive fertility solution can simultaneously ...

Highlights
The EPS has grown by 36% year-on-year and by 18% since the previous quarter
The net income has grown by 29% YoY and by 16% from the previous quarter
The stock's price to earnings (P/E) is 28% less than its 5-year quarterly average of 53.8 but 22% more than its last 4 quarters average of 32.0
PGNY's quick ratio is down by 21% since the previous quarter and by 12% year-on-year
PGNY's equity is down by 15% since the previous quarter and by 6% year-on-year
Sector: Healthcare
Industry: Health Information Services
Website: http://www.progyny.com

Key stats

What are the main financial stats of PGNY

PGNY stock price

How has the Progyny stock price performed over time
Intraday
1.6%
1 week
-2.32%
1 month
15.99%
1 year
35.61%
YTD
21.46%
QTD
8.19%

Financial performance

How have Progyny's revenue and profit performed over time
Revenue
$1.29B
Gross profit
$311.76M
Operating income
$96.49M
Net income
$67.69M
Gross margin
24.1%
Net margin
5.2%
Progyny's operating income has increased by 32% YoY and by 13% QoQ
The net income has grown by 29% YoY and by 16% from the previous quarter
PGNY's operating margin is up by 25% year-on-year and by 14% since the previous quarter
The company's net margin rose by 21% YoY and by 16% QoQ

Price vs fundamentals

How does PGNY's price correlate with its fundamentals

Growth

What is Progyny's growth rate over time

Valuation

What is Progyny stock price valuation
PGNY P/E details
P/E
38.99
P/B
5.81
P/S
1.95
EV/EBIT
22.07
EV/EBITDA
21.02
EV/Sales
1.81
The EPS has grown by 36% year-on-year and by 18% since the previous quarter
The stock's price to earnings (P/E) is 28% less than its 5-year quarterly average of 53.8 but 22% more than its last 4 quarters average of 32.0
PGNY's price to book (P/B) is 61% higher than its last 4 quarters average of 3.6 but 26% lower than its 5-year quarterly average of 7.8
PGNY's equity is down by 15% since the previous quarter and by 6% year-on-year
PGNY's price to sales (P/S) is 47% lower than its 5-year quarterly average of 3.7 but 39% higher than its last 4 quarters average of 1.4
The revenue is up by 7% year-on-year

Efficiency

How efficient is Progyny business performance
Progyny's return on assets has increased by 17% QoQ and by 15% YoY
The company's return on equity rose by 17% QoQ and by 13% YoY
PGNY's return on invested capital is up by 15% since the previous quarter and by 5% year-on-year
The return on sales has grown by 14% year-on-year and by 11% since the previous quarter

Dividends

What is PGNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PGNY.

Financial health

How did Progyny financials performed over time
PGNY's total assets is 170% more than its total liabilities
Progyny's current ratio has decreased by 22% QoQ and by 11% YoY
PGNY's quick ratio is down by 21% since the previous quarter and by 12% year-on-year
The company's debt is 95% lower than its equity
PGNY's debt to equity is down by 17% year-on-year
PGNY's equity is down by 15% since the previous quarter and by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.